AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10195546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 76
Study 10195546 — intervention group
Group type: COMPARATOR
Intervention: Propofol 3 mg/kg
Number of subjects: 76
Study 7773026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support program
Number of subjects: 113
Study 7773026 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 113
Study 7773026 — intervention group
Group type: COMPARATOR
Intervention: Married men
Number of subjects: 113
Study 1971629 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal colonization by coliforms
Number of subjects: 0
Study 1971629 — intervention group
Group type: COMPARATOR
Intervention: Bacteriuria
Number of subjects: 0
Study 7428401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg, 1 dose
Number of subjects: 49
Study 7428401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg, 7 doses
Number of subjects: 49
Study 7428401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g, 1 dose
Number of subjects: 49
Study 7428401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g, 7 doses
Number of subjects: 49
Study 31330250 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score with 50% compliance and 0% informed deviation (ID)
Number of subjects: 0
Study 31330250 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score with any compliance and at least 50% ID
Number of subjects: 0
Study 31330250 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score with higher compliance and ID scenarios
Number of subjects: 0
Study 28701627 — intervention group
Group type: EXPERIMENTAL
Intervention: Typing I (keyboard slope 0°)
Number of subjects: 15
Study 28701627 — intervention group
Group type: EXPERIMENTAL
Intervention: Typing II (keyboard slope 20°)
Number of subjects: 15
Study 28701627 — intervention group
Group type: COMPARATOR
Intervention: Control (no typing)
Number of subjects: 15
Study 25446600 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG-30% extract
Number of subjects: 13
Study 25446600 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-50% extract
Number of subjects: 13
Study 25446600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 13
Study 23548545 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training program (LTP)
Number of subjects: 469
Study 21679530 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic septal splint
Number of subjects: 40
Study 18938041 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with CAH
Number of subjects: 128
Study 18938041 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with CAH
Number of subjects: 128
Study 18938041 — intervention group
Group type: COMPARATOR
Intervention: Unaffected females
Number of subjects: 128
Study 18938041 — intervention group
Group type: COMPARATOR
Intervention: Unaffected males
Number of subjects: 128
Study 17125424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus intravaginal capsule
Number of subjects: 424
Study 17125424 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravaginal capsule
Number of subjects: 424
Study 14702508 — intervention group
Group type: EXPERIMENTAL
Intervention: One-page summary of clinical practice guidelines
Number of subjects: 3293
Study 14702508 — intervention group
Group type: EXPERIMENTAL
Intervention: One-page summary of clinical practice guidelines and a reminder
Number of subjects: 3293
Study 14702508 — intervention group
Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 3293
Study 14702508 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prescription rates (all groups)
Number of subjects: 3293
Study 10357054 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 39
Study 10357054 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 39
Study 8533342 — intervention group
Group type: EXPERIMENTAL
Intervention: Human object-recognition efficiency
Number of subjects: 0
Study 8533342 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting recognition efficiency
Number of subjects: 0
Study 8533342 — intervention group
Group type: EXPERIMENTAL
Intervention: Other factors affecting recognition efficiency
Number of subjects: 0
Study 2039190 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule 2 (30 mg/kg over 2 days; one dose of 10 mg/kg followed by two doses of 5 mg/kg at 6‐h intervals on the first day and two doses of 5 mg/kg at 12‐h intervals on the second day)
Number of subjects: 27
Study 2039190 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule 2
Number of subjects: 27
Study 2039190 — intervention group
Group type: COMPARATOR
Intervention: Schedule 1 (25 mg/kg over 3 days)
Number of subjects: 27
Study 2039190 — intervention group
Group type: COMPARATOR
Intervention: Schedule 1
Number of subjects: 27
Study 6165255 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin
Number of subjects: 0
Study 6165255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 60
Number of subjects: 0
Study 31793465 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 30
Study 31793465 — intervention group
Group type: COMPARATOR
Intervention: Control (200 mL of tap water)
Number of subjects: 30
Study 28947390 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM at 33°C
Number of subjects: 163
Study 28947390 — intervention group
Group type: COMPARATOR
Intervention: TTM at 36°C
Number of subjects: 163
Study 24606094 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 FAEE supplementation (4 g/d)
Number of subjects: 25
Study 24606094 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet alone (Control)
Number of subjects: 25
Study 24606094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (ω-3 FAEE and control)
Number of subjects: 25
Study 22500390 — intervention group
Group type: EXPERIMENTAL
Intervention: Busui Shengxue Granule (BSSXG)
Number of subjects: 124
Study 22500390 — intervention group
Group type: COMPARATOR
Intervention: Zaizao Shengxue Tablet (ZST)
Number of subjects: 124
Study 20598391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive information package (written information and a telephone call from the research nurse)
Number of subjects: 194
Study 20598391 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 194
Study 17559735 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa correction/maintenance dosing (4.5 microg/kg weekly for 4 weeks followed by 4.5 microg/kg every 3 weeks)
Number of subjects: 0
Study 17559735 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa weekly dosing (2.25 microg/kg weekly)
Number of subjects: 0
Study 17559735 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa correction/maintenance dosing
Number of subjects: 0
Study 17559735 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa weekly dosing
Number of subjects: 0
Study 17559735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 16127110 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meals for dinner
Number of subjects: 34
Study 12383323 — intervention group
Group type: EXPERIMENTAL
Intervention: SAE-HyCoSy with Levovist contrast medium and maximum acoustic power
Number of subjects: 41
Study 12383323 — intervention group
Group type: COMPARATOR
Intervention: HSG (X-ray hysterosalpingography)
Number of subjects: 41
Study 12383323 — intervention group
Group type: EXPERIMENTAL
Intervention: SAE-HyCoSy
Number of subjects: 41
Study 10408592 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (200 or 300 mg b.i.d.)
Number of subjects: 528
Study 10408592 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5‐20 mg u.i.d.)
Number of subjects: 528
Study 10408592 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 528
Study 10408592 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 528
Study 7677298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg administered alone
Number of subjects: 12
Study 7677298 — intervention group
Group type: COMPARATOR
Intervention: Dapsone 100 mg administered with didanosine placebo tablets (group 1)
Number of subjects: 12
Study 7677298 — intervention group
Group type: COMPARATOR
Intervention: Dapsone 100 mg administered with active didanosine tablets (group 2)
Number of subjects: 12
Study 1698170 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser panretinal photocoagulation (PRP)
Number of subjects: 123
Study 1698170 — intervention group
Group type: COMPARATOR
Intervention: Non-lasered eyes (control group)
Number of subjects: 123
Study 6754492 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g oral glucose tolerance test
Number of subjects: 19
Study 6754492 — intervention group
Group type: COMPARATOR
Intervention: Standardized breakfast meal of equivalent carbohydrate content
Number of subjects: 19
Study 31905410 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic suspension allograft injection
Number of subjects: 0
Study 31905410 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 0
Study 31905410 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 27662576 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-kVp Sn protocol
Number of subjects: 75
Study 27662576 — intervention group
Group type: COMPARATOR
Intervention: 70-kVp protocol
Number of subjects: 75
Study 27132075 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthlines Depression Service plus usual care
Number of subjects: 609
Study 27132075 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 609
Study 25063416 — intervention group
Group type: EXPERIMENTAL
Intervention: HMZ-T2 head-mounted display
Number of subjects: 0
Study 25063416 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrap1200 head-mounted display
Number of subjects: 0
Study 25063416 — intervention group
Group type: COMPARATOR
Intervention: Fixed-site monitor
Number of subjects: 0
Study 21986184 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 12
Study 21986184 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 12
Study 21986184 — intervention group
Group type: COMPARATOR
Intervention: No access to fluids (NF)
Number of subjects: 12
Study 19499845 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol plus folic acid
Number of subjects: 42
Study 17498420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent minocycline mouthwash
Number of subjects: 17
Study 17498420 — intervention group
Group type: COMPARATOR
Intervention: 0.25 percent tetracycline aqueous solution mouthwash
Number of subjects: 17
Study 18005429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of folic acid
Number of subjects: 730
Study 18005429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 15160440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg (R20)
Number of subjects: 339
Study 15160440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg (R10)
Number of subjects: 339
Study 15160440 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg (L10)
Number of subjects: 339
Study 11129253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water exposure for patients with ET
Number of subjects: 40
Study 11129253 — intervention group
Group type: COMPARATOR
Intervention: Warm water exposure for patients with ET
Number of subjects: 40
Study 11129253 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water exposure for patients with PD
Number of subjects: 40
Study 11129253 — intervention group
Group type: COMPARATOR
Intervention: Cold water exposure for patients with PD
Number of subjects: 40
Study 9190233 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to organic dust and microorganisms
Number of subjects: 31
Study 1385586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (3.2 g for the first month, thereafter 1.6 g)
Number of subjects: 75
Study 1385586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1385586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (3.2 g and 1.6 g)
Number of subjects: 75
Study 1385586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (3.2 g)
Number of subjects: 75
Study 1385586 — intervention group
Group type: COMPARATOR
Intervention: Clodronate and Placebo
Number of subjects: 75
Study 6719513 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tomography for localization of treatment volume
Number of subjects: 55
Study 6719513 — intervention group
Group type: COMPARATOR
Intervention: Conventional localization for treatment volume
Number of subjects: 55
Study 30808670 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fasciectomy
Number of subjects: 56
Study 30808670 — intervention group
Group type: COMPARATOR
Intervention: Collagenase injection
Number of subjects: 56
Study 30808670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study 29278896 — intervention group
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Number of subjects: 12
Study 27296126 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan‐coated polyglactin 910 with 2‐octylcyanoacrylate‐based adhesive (group 1)
Number of subjects: 322
Study 27296126 — intervention group
Group type: COMPARATOR
Intervention: Non‐triclosan‐coated polyglactin 910 (group 2)
Number of subjects: 322
Study 27296126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preventive measures (CPM) including antibiotic prophylaxis with IV amoxicillin/clavulanate (1.2 g)
Number of subjects: 322
Study 27296126 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (AP)
Number of subjects: 322
Study 25186922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 1049
Study 25186922 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 1049
Study 21983238 — intervention group
Group type: EXPERIMENTAL
Intervention: Erotic video clip
Number of subjects: 12
Study 21983238 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous video clip
Number of subjects: 12
Study 21983238 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive video clip
Number of subjects: 12
Study 21983238 — intervention group
Group type: EXPERIMENTAL
Intervention: Training motivational video clip
Number of subjects: 12
Study 21983238 — intervention group
Group type: COMPARATOR
Intervention: Sad video clip
Number of subjects: 12
Study 21983238 — intervention group
Group type: COMPARATOR
Intervention: Neutral control video clip
Number of subjects: 12
Study 19618659 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based fitness program
Number of subjects: 35
Study 17804941 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention as supportive nursing care
Number of subjects: 51
Study 17804941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone intervention)
Number of subjects: 51
Study 15156418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia (TIVA)
Number of subjects: 52
Study 15156418 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia (BA)
Number of subjects: 52
Study 11642085 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg
Number of subjects: 213
Study 11642085 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 213
Study 9840720 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid co-medication
Number of subjects: 87
Study 9840720 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel without corticosteroid co-medication
Number of subjects: 87
Study 9840720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose of docetaxel
Number of subjects: 87
Study 8030804 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium, 2% ophthalmic solution, bid
Number of subjects: 86
Study 8030804 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 2723121 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxanox sodium
Number of subjects: 15
Study 2723121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30903806 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment of severe wasting
Number of subjects: 1542
Study 27696393 — intervention group
Group type: EXPERIMENTAL
Intervention: 3hC+ (3-hour MAL application with curettage)
Number of subjects: 22
Study 27696393 — intervention group
Group type: EXPERIMENTAL
Intervention: 21hC- (21-hour MAL application without curettage)
Number of subjects: 22
Study 27696393 — intervention group
Group type: EXPERIMENTAL
Intervention: 21hC+ (21-hour MAL application with curettage)
Number of subjects: 22
Study 27696393 — intervention group
Group type: COMPARATOR
Intervention: 3hC- (3-hour MAL application without prior curettage)
Number of subjects: 22
Study 27696393 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended MAL application with and without curettage
Number of subjects: 22
Study 27696393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and erythema
Number of subjects: 22
Study 25447557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine at 1 mg/kg
Number of subjects: 80
Study 25447557 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fentanyl at 1.5 μg/kg
Number of subjects: 80
Study 24411639 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus nintedanib
Number of subjects: 1314
Study 22963131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0
Study 22963131 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/Cisplatin (Gem/Cis)
Number of subjects: 0
Study 22963131 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed/Cisplatin (Pem/Cis)
Number of subjects: 0
Study 22963131 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/Carboplatin (Pac/Carb)
Number of subjects: 0
Study 20023346 — intervention group
Group type: EXPERIMENTAL
Intervention: External oblique abdominis muscle activation during loading 12 kg in flexed trunk position
Number of subjects: 20
Study 20023346 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal oblique abdominis muscle activation during loading 6 and 12 kg in neutral trunk position
Number of subjects: 20
Study 20023346 — intervention group
Group type: COMPARATOR
Intervention: Electrical activity of back muscles during trunk flexion with highest external load
Number of subjects: 20
Study 20023346 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of Rectus abdominis muscle in patients with CLBP during increasing load
Number of subjects: 20
Study 20023346 — intervention group
Group type: COMPARATOR
Intervention: Activation of Rectus abdominis and Internal oblique muscles in healthy subjects during increasing load
Number of subjects: 20
Study 17540215 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Number of subjects: 18
Study 17540215 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) in IPAH patients
Number of subjects: 18
Study 17540215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-mediated dilation in IPAH patients
Number of subjects: 18
Study 17540215 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of FMD with PVRII
Number of subjects: 18
Study 15384808 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (oral)
Number of subjects: 36
Study 15384808 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (oral)
Number of subjects: 36
Study 15384808 — intervention group
Group type: COMPARATOR
Intervention: Ca channel blocker
Number of subjects: 36
Study 12891152 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL)
Number of subjects: 32
Study 12891152 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based case format
Number of subjects: 32
Study 10626618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (child only)
Number of subjects: 100
Study 10626618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (mother only)
Number of subjects: 100
Study 10626618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (mother and child)
Number of subjects: 100
Study 10626618 — intervention group
Group type: COMPARATOR
Intervention: Community comparison condition
Number of subjects: 100
Study 8748193 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) for three 3‐h periods daily
Number of subjects: 5
Study 8748193 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 5
Study 8748193 — intervention group
Group type: EXPERIMENTAL
Intervention: Both limbs (CPM and Control)
Number of subjects: 5
Study 2202511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 gm single dose)
Number of subjects: 62
Study 2202511 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 gm)
Number of subjects: 62
Study 7285499 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 8
Study 7285499 — intervention group
Group type: COMPARATOR
Intervention: Control (no indomethacin)
Number of subjects: 8
Study 30740991 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry postponement intervention (postponing worries to a 30-minute period in the evening)
Number of subjects: 114
Study 30740991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 114
Study 28857336 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of periodized aerobic training
Number of subjects: 24
Study 28857336 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 matched subjects, age 64 ± 5 years; FEV1 %pred 113 ± 16%)
Number of subjects: 24
Study 25643859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour online auditory training programme
Number of subjects: 162
Study 25643859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year mastery-style reinforcement programme
Number of subjects: 162
Study 25643859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 162
Study 24452619 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 106
Study 24452619 — intervention group
Group type: COMPARATOR
Intervention: TVT-S
Number of subjects: 106